Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician’s conundrum

References

• Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut 60(12), 1754–1763 (2011).
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 135(4), 1114–1122 (2008).
   PubMed Web of Science ®Google Scholar
• Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn’s disease: analysis according to the vienna classification and clinical activity. Inflamm. Bowel Dis. 7(4), 306–313 (2001)
   PubMed Web of Science ®Google Scholar
• Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and Crohn disease. Gastroenterol. Clin. North Am. 41(2), 443–462 (2012).
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis. 8(4), 244–250 (2002).
   PubMed Web of Science ®Google Scholar
• Vernier-Massouille G, Balde M, Salleron J et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology 135(4), 1106–1113 (2008).
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J et al.; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44(4), 431–440 (2009).
   PubMed Web of Science ®Google Scholar
• Witte J, Shivananda S, Lennard-Jones JE et al. Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand. J. Gastroenterol. 35(12), 1272–1277 (2000).
   PubMed Web of Science ®Google Scholar
• Heyman MB, Kirschner BS, Gold BD et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J. Pediatr. 146(1), 35–40 (2005).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Judd RH, Hoffmann RG et al.; Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr. 143(4), 525–531 (2003).
   PubMed Web of Science ®Google Scholar
• Gower-Rousseau C, Dauchet L, Vernier-Massouille G et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 104(8), 2080–2088 (2009).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD; Inflammatory Bowel Disease Center. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm. Bowel Dis. 12(10), 972–978 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann. Intern. Med. 133(10), 795–799 (2000).
   PubMed Web of Science ®Google Scholar
• Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 53(2), 251–255 (2004).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O’Fallon WM, Melton LJ 3rd. Long-term fracture risk in patients with Crohn’s disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 123(2), 468–475 (2002).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm. Bowel Dis. 17(1), 471–478 (2011).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85(3), 430–434 (2001).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 6(1), 41–45 (2008).
   PubMed Web of Science ®Google Scholar
• Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138(2), 746–774.e1 (2010).
   PubMed Web of Science ®Google Scholar
• Gupta N, Cohen SA, Bostrom AG et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology 130(4), 1069–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Schaefer ME, Machan JT, Kawatu D et al. Factors that determine risk for surgery in pediatric patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 8(9), 789–794 (2010).
   PubMed Web of Science ®Google Scholar
• Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am. J. Gastroenterol. 97(4), 947–953 (2002).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lin YC, Dutridge D et al.; Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am. J. Gastroenterol. 101(2), 360–367 (2006).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Kugathasan S, Mei L et al.; Western Regional Pediatric IBD Research Alliance; Pediatric IBD Collaborative Research Group; Wisconsin Pediatric IBD Alliance. Increased immune reactivity predicts aggressive complicating Crohn’s disease in children. Clin. Gastroenterol. Hepatol. 6(10), 1105–1111 (2008).
   PubMed Web of Science ®Google Scholar
• Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology 123(3), 679–688 (2002).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Targan SR, Dubinsky MC et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s disease behavior. Inflamm. Bowel Dis. 17(12), 2488–2496 (2011).
   PubMed Web of Science ®Google Scholar
• Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9(10), 599–608 (2012).
   PubMed Web of Science ®Google Scholar
• Sartor RB. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol. 4(2), 127–132 (2011).
   PubMed Web of Science ®Google Scholar
• Gulati AS, Dubinsky MC. Probiotics in pediatric inflammatory bowel diseases. Curr. Gastroenterol. Rep. 11(3), 238–247 (2009).
   PubMedGoogle Scholar
• Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 60(1), 49–54 (2011).
   PubMed Web of Science ®Google Scholar
• Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136(6), 2015–2031 (2009).
   PubMed Web of Science ®Google Scholar
• Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 4(12), e413 (2006).
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 1(6), 6ra14 (2009).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin. Gastroenterol. Hepatol. 9(6), 483–489.e3 (2011).
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G et al.; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 138(2), 463–468; quiz e10 (2010).
   PubMed Web of Science ®Google Scholar
• Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol. Hepatol. (NY) 8(1), 29–38 (2012).
   PubMedGoogle Scholar
• Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133(2), 412–422 (2007).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis. 15(9), 1295–1301 (2009).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F et al.; Scientific Committee of the European Crohn’s and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J. Crohns. Colitis 5(5), 477–483 (2011).
   PubMed Web of Science ®Google Scholar
• Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. 15(11), 1755–1764 (2009).
   PubMed Web of Science ®Google Scholar
• Savoye G, Salleron J, Gower-Rousseau C et al. Clinical predictors at diagnosis of disabling pediatric Crohn’s disease. Inflamm. Bowel Dis. 18(11), 2072–2078 (2012).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Lémann M, Befrits R et al. Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm. Bowel Dis. 18(1), 152–160 (2012).
   PubMed Web of Science ®Google Scholar
• Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev. Clin. Immunol. 6(4), 659–666 (2010).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362(15), 1383–1395 (2010).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705–713 (2000).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Loftus EV Jr, Binion D et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial. Can. J. Gastroenterol. 25(8), 419–425 (2011).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med. 357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al.; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med. 357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Chaparro M, Panés J, García V et al. Long-term durability of response to adalimumab in Crohn’s disease. Inflamm. Bowel Dis. 18(4), 685–690 (2012).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ et al.; EXTEND Investigators. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 142(5), 1102–1111.e2 (2012).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Mcdonald JW, Panaccione R, Enns RA. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn’s disease. Gastroenterology 135(1), 294–295 (2008).
   Google Scholar
• Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 56(9), 1226–1231 (2007).
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S et al.; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132(3), 863–873; quiz 1165 (2007).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Griffiths A, Markowitz J et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 143(2), 365–374.e2 (2012).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6), 780–787 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–265.e1 (2012).
   PubMed Web of Science ®Google Scholar
• Hyams J, Damaraju L, Blank M et al.; T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 10(4), 391–399.e1 (2012).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment. Pharmacol. Ther. 23(8), 1127–1136 (2006).
   PubMed Web of Science ®Google Scholar
• Papa A, Mocci G, Bonizzi M et al. Use of infliximab in particular clinical settings: management based on current evidence. Am. J. Gastroenterol. 104(6), 1575–1586 (2009).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am. J. Gastroenterol. 104(3), 760–767 (2009).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348(7), 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124(4), 917–924 (2003).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134(7), 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G et al.; Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63–70; quiz e31 (2012).
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64(10), 1414–1420 (2005).
   PubMed Web of Science ®Google Scholar
• Beukelman T, Haynes K, Curtis JR et al.; Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 64(4), 1263–1271 (2012).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56(5), 1433–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121(5), 1080–1087 (2001).
   PubMed Web of Science ®Google Scholar
• Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7(8), 874–881 (2009).
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM et al.; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374(9701), 1617–1625 (2009).
   PubMed Web of Science ®Google Scholar
• Dayharsh GA, Loftus EV Jr, Sandborn WJ et al. Epstein–Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122(1), 72–77 (2002).
   PubMed Web of Science ®Google Scholar
• Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm. Bowel Dis. 18(5), 838–843 (2012).
   PubMed Web of Science ®Google Scholar
• Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-a inhibitor therapy: expanding the groups at risk. Eur. J. Gastroenterol. Hepatol. 23(12), 1150–1156 (2011).
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 9(1), 36–41.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis. 68(7), 1100–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Rosenberg AM, Oen KG et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J. Rheumatol. 38(4), 760–763 (2011).
   PubMed Web of Science ®Google Scholar
• Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317(7152), 180–181 (1998).
   PubMed Web of Science ®Google Scholar
• Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst. 85(4), 307–311 (1993).
   PubMed Web of Science ®Google Scholar
• Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am. J. Med. 78(1A), 15–21 (1985).
   PubMed Web of Science ®Google Scholar
• Sinagra E, Romano C, Virdone R, Orlando E, Cottone M, Orlando A. An unusual presentation of T-lymphoma in a Crohn’s disease patient treated with combo therapy: we are willing to take a risk of serious adverse events for a doubtful benefit? J. Crohns. Colitis 6(9), 954–955 (2012).
   PubMed Web of Science ®Google Scholar